NO20054169L - 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. - Google Patents
3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.Info
- Publication number
- NO20054169L NO20054169L NO20054169A NO20054169A NO20054169L NO 20054169 L NO20054169 L NO 20054169L NO 20054169 A NO20054169 A NO 20054169A NO 20054169 A NO20054169 A NO 20054169A NO 20054169 L NO20054169 L NO 20054169L
- Authority
- NO
- Norway
- Prior art keywords
- propylcarbamoyl
- benzothiazol
- cycloalkyl
- inhibitors
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305916A GB0305916D0 (en) | 2003-03-14 | 2003-03-14 | New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors |
| GB0329143A GB0329143D0 (en) | 2003-12-16 | 2003-12-16 | Novel pharmaceuticals |
| PCT/IB2004/000822 WO2004080985A1 (en) | 2003-03-14 | 2004-03-09 | 3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as nep inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054169D0 NO20054169D0 (no) | 2005-09-07 |
| NO20054169L true NO20054169L (no) | 2005-12-07 |
Family
ID=32992599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054169A NO20054169L (no) | 2003-03-14 | 2005-09-07 | 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20040180941A1 (es) |
| EP (1) | EP1606272A1 (es) |
| JP (1) | JP3923512B2 (es) |
| KR (1) | KR20050110003A (es) |
| AP (1) | AP2005003393A0 (es) |
| AR (1) | AR043551A1 (es) |
| AU (1) | AU2004220269A1 (es) |
| BR (1) | BRPI0408377A (es) |
| CA (1) | CA2519072A1 (es) |
| CL (1) | CL2004000512A1 (es) |
| EA (1) | EA200501204A1 (es) |
| EC (1) | ECSP056017A (es) |
| HR (1) | HRP20050797A2 (es) |
| IS (1) | IS8003A (es) |
| MA (1) | MA27720A1 (es) |
| MX (1) | MXPA05009788A (es) |
| NL (1) | NL1025709C2 (es) |
| NO (1) | NO20054169L (es) |
| OA (1) | OA13039A (es) |
| PA (1) | PA8597401A1 (es) |
| PE (1) | PE20050310A1 (es) |
| TN (1) | TNSN05227A1 (es) |
| TW (1) | TW200504038A (es) |
| UY (1) | UY28226A1 (es) |
| WO (1) | WO2004080985A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2575706A1 (en) * | 2004-08-02 | 2006-02-23 | Bebaas, Inc. | Vitamin b12 compositions |
| WO2006027680A1 (en) * | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| ES2425567T3 (es) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Método de tratamiento o profilaxis |
| KR20080047375A (ko) | 2005-07-29 | 2008-05-28 | 콘서트 파마슈티컬즈, 인크. | 약제 화합물 |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| CN102885818B (zh) | 2006-03-20 | 2016-05-04 | 诺华股份有限公司 | 治疗或预防炎性痛的方法 |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| KR101177866B1 (ko) | 2011-03-24 | 2012-08-28 | 주식회사 케이엠더블유 | 케이블 접속 장치 |
| JP2021527267A (ja) * | 2018-06-14 | 2021-10-11 | アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ | Ｃｇｍｐ特異的ホスホジエステラーゼ５阻害剤の薬学的組成物により勃起不全を治療するための方法 |
| CN112955967A (zh) * | 2018-06-14 | 2021-06-11 | 阿斯利康(英国)有限公司 | 用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法 |
| IL292775A (en) * | 2019-11-08 | 2022-07-01 | Vella Bioscience Inc | preparations containing cannabidiol (cbd) that act peripherally and their use to improve female sexual function or to treat female sexual disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2503059A (en) * | 1950-04-04 | Nxchj | ||
| US2599000A (en) * | 1950-09-02 | 1952-06-03 | Smith Kline French Lab | Nu, nu-disubstituted-beta-halo-alkylamines |
| US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| IT1066857B (it) * | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| NL175059C (nl) * | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. | |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
| IT1094076B (it) * | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
| JPS56110665A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| DE3528032A1 (de) * | 1985-08-05 | 1987-02-05 | Hoechst Ag | Verfahren zur herstellung 2-substituierter benzthiazole |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US5698560A (en) * | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| OA12553A (en) * | 2001-03-28 | 2006-06-07 | Pfizer | N-Phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD. |
-
2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/en active Application Filing
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 EP EP04718706A patent/EP1606272A1/en not_active Withdrawn
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Application Discontinuation
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-09 CA CA002519072A patent/CA2519072A1/en not_active Abandoned
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
-
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-12 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0408377A (pt) | 2006-03-21 |
| JP3923512B2 (ja) | 2007-06-06 |
| IS8003A (is) | 2005-08-29 |
| EP1606272A1 (en) | 2005-12-21 |
| ECSP056017A (es) | 2006-01-27 |
| MA27720A1 (fr) | 2006-01-02 |
| AP2005003393A0 (en) | 2005-09-30 |
| KR20050110003A (ko) | 2005-11-22 |
| PE20050310A1 (es) | 2005-05-04 |
| EA200501204A1 (ru) | 2006-06-30 |
| AU2004220269A1 (en) | 2004-09-23 |
| OA13039A (en) | 2006-11-10 |
| PA8597401A1 (es) | 2005-05-24 |
| CA2519072A1 (en) | 2004-09-23 |
| TNSN05227A1 (fr) | 2007-06-11 |
| JP2006526572A (ja) | 2006-11-24 |
| AR043551A1 (es) | 2005-08-03 |
| NL1025709A1 (nl) | 2004-09-16 |
| US20040180941A1 (en) | 2004-09-16 |
| UY28226A1 (es) | 2004-11-08 |
| CL2004000512A1 (es) | 2005-01-21 |
| TW200504038A (en) | 2005-02-01 |
| WO2004080985A1 (en) | 2004-09-23 |
| MXPA05009788A (es) | 2005-10-26 |
| HRP20050797A2 (en) | 2006-02-28 |
| NL1025709C2 (nl) | 2005-03-14 |
| NO20054169D0 (no) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054169L (no) | 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. | |
| NO20052796L (no) | Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| NO20091560L (no) | Biaryleterureaforbindelser | |
| NO20053627L (no) | Malonamidderivater som gamma-sekretase inhibitorer | |
| NO20083411L (no) | Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling | |
| NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| NO20051189L (no) | 1,3-diamino-2-hydroksypropan prodrogederivater | |
| NO20082496L (no) | Pyrazinderivater | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| MY162022A (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| TW200726767A (en) | Chemical compounds 2 | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| BRPI0409627A (pt) | 2-hidróxi-3-diaminoalcanos de fenacila | |
| EP1689713A4 (en) | BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | |
| NO20060314L (no) | Nicotinamid-derivater anvendbare som PDE4-inhibitorer | |
| EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| ATE489951T1 (de) | Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
| NO20051011L (no) | Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister | |
| TW200745106A (en) | Chemical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |